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Abstract
Background: Programmed cell death protein-1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have
remarkable clinical efficacy in the treatment of non-small cell lung cancer (NSCLC); however, the breakdown of
immune escape causes a variety of immune-related adverse events (irAEs). With the increasing use of PD-1/PD-L1
inhibitors alone or in combination with other therapies, awareness and management of irAEs have become more
important. We aimed to assess the incidence and nature of irAEs associated with PD-1 and PD-L1 inhibitors for
NSCLC.
Methods: Articles from the MEDLINE, EMBASE, and Cochrane databases were searched through December 2017. The
incidence of overall and organ-specific irAEs was investigated in all clinical trials with nivolumab, pembrolizumab,
atezolimumab, durvalumab, and avelumab as single agents for treatment of NSCLC. We calculated the pooled
incidence using R software with package Meta.
Results: Sixteen trials were included in the meta-analysis: 10 trials with PD-1 inhibitors (3734 patients) and 6
trials with PD-L1 inhibitors (2474 patients). The overall incidence of irAEs was 22% (95% confidence interval
[CI], 17–28) for all grades and 4% (95% CI, 2–6) for high-grade irAEs. The frequency of irAEs varied based on
drug type and organ, and patients treated with PD-1 inhibitors had an increased rate of any grade and high-
grade irAEs compared with patients who received PD-L1 inhibitors. Organ-specific irAEs were most frequently
observed in, in decreasing order, the endocrine system, skin, pulmonary tract, and gastrointestinal tract. The
total number of patients whose death was attributed to irAEs was 14 (0.34%), and most (79%) of these
patients died because of pneumonitis. The median time to the onset of irAEs after the initiation of treatment
was 10 weeks (interquartile range, 6–19.5 weeks) and varied depending on the organ system involved.
Conclusions: The specificity of irAEs was closely associated with the mechanism of PD-1/PD-L1 antibodies
involved in restarting anticancer immune attacks. Comprehensive understanding, timely detection, and
effective management could improve the compliance of patients and guide the interruption of treatment.
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Background
Programmed cell death protein-1 (PD-1) is an important
immunologic checkpoint inhibitor (ICI) that was discov-
ered after cytotoxic T-lymphocyte-associated antigen-4
(CTLA-4). In 2002, a study using cloned antibodies in a
mouse model showed that local immunosuppression can
be abolished by blocking the binding of PD-1 and pro-
grammed cell death ligand 1 (PD-L1) [1]. This strategy
established the basis for using PD-1/PD-L1 monoclonal
antibodies to treat tumors. Since that time, the full lever-
age of the immune system’s potential has opened a new
era of cancer treatment.
Inhibitors of PD-1 and PD-L1 act as ICIs by relaunch-
ing T cell-mediated tumor cell death programs (Fig. 1).
These inhibitors have shown promising clinical efficacy
in the treatment of non-small cell lung cancer (NSCLC),
which remains a leading cause of cancer-related mortal-
ity [2]. PD-1 inhibitors pembrolizumab and nivolumab
as well as the PD-L1 inhibitors atezolizumab, avelumab,
and durvalumab have all been approved in succession by
the Food and Drug Administration (FDA) for treating
patients with metastatic NSCLC. Moreover, pembrolizu-
mab was recently approved for first-line treatment of
metastatic NSCLC (i.e., high PD-L1 expression, ≥50%;
no epidermal growth factor receptor; or anaplastic
lymphoma kinase mutation). In addition, pembrolizu-
mab has been approved for adult and childhood cancer
patients for the treatment of unresectable or metastatic
solid tumors with the molecular features of high micro-
satellite instability or mismatch repair deficiency. The
use of the same treatment for different diseases signifies
a deeper and more comprehensive understanding of
cancer and represents an important milestone in preci-
sion medicine.
Many clinical trials have been conducted to assess the
efficacy and safety of PD-1/PD-L1 inhibitors used in
combination with oncolytic virotherapy [3], anti-CTLA-
4 antibodies [4, 5], targeted therapy [6], chemotherapy
[7], or other means [8]. The increase in combined appli-
cations has made it difficult to evaluate safety. For ex-
ample, grade 3–4 treatment-related adverse events
(trAEs) were reported in 37, 33, and 48% of patients in
two cohorts of one study [4] and in another study [5],
respectively, involving treatment with nivolumab plus
ipilimumab. It should be noted that these studies did
not focus on irAEs, and it is not possible to distinguish
which drug of a combination causes trAEs. Such safety
assessment does not provide a unified reference for
clinicians. Therefore, it is essential to conduct a
meta-analysis and systematic review to evaluate the
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Fig. 1 Mechanism of action of PD-1 and PD-L1 inhibitors (a) PD-1/PD-L1 binding inhibits T cell killing of tumor cells. b Blocking PD-L1 or PD-1
allows T cell killing. c Overview of the mechanism: APC T cell interaction T cell activation (i.e., cytokine secretion, lysis, proliferation, migration to
tumor) Tumor microenvironment.
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irAEs of PD-1 and PD-L1 inhibitors alone in the treat-
ment of NSCLC.
Inhibitors of PD-1 and PD-L1 interfere with normal
mechanisms of immune tolerance while inhibiting tumor
immune escape. The increase in immune activation
caused by these inhibitors in normal tissues may be re-
sponsible for various types of significant irAEs, which in-
clude endocrine, skin, pulmonary, gastrointestinal,
hepatic, renal, neurologic, cardiac, and hematologic
autoimmune diseases. IrAEs can negatively influence a
patient’s quality of life and interrupt oncology treatment;
therefore, sufficient knowledge, on-time monitoring, and
appropriate management of these events are important.
Although two reports have reviewed the safety of PD-1
and PD-L1 inhibitors in the treatment of malignancies,
the results were not entirely consistent [9, 10], and to
our knowledge, no systematic reviews or meta-analyses
of irAEs associated with PD-1/PD-L1 inhibitors for
NSCLC using the Common Terminology Criteria as the
outcome metric have been published in the literature.
Thus, we conducted a systematic review and
meta-analysis of the qualifying literature aiming to assess
the incidence and nature of irAEs resulting from the use
of anti-PD-1 or anti-PD-L1 antibodies to treat NSCLC.
Methods
Developed using the stepwise approach to systematic re-
views described by Kelley and Kelley [11], the protocol
of our systematic review and meta-analysis has been reg-
istered in the International Prospective Register of Sys-
tematic Reviews (PROSPERO) (No. CRD42016045886)
and has been previously published [12].
Data sources and searches
A systematic literature search for relevant articles pub-
lished in any language through December 2017 was con-
ducted using EMBASE, MEDLINE via PubMed, and the
Cochrane Central Register of Controlled Trials. Two in-
vestigators (XYS and SYC) together determined the final
search strategy. The detailed search strategy for PubMed
was provided in Additional file 1: Table S1. Searches
were repeated immediately before the final analysis to
identify additional studies for inclusion, and manual
searches were also conducted from references of related
literature, both of which were done by XYS. Articles
published as full texts were optimal to extract data re-
lated to irAEs in detail and to allow a quality assessment
of the trials included in the meta-analysis. Therefore, un-
published studies were not searched or included. End-
Note X7 software was used to store references.
Eligibility criteria and study selection
We included randomized controlled trials (RCTs),
single-arm trials, and case reports that reported irAEs in
patients with a diagnosis of NSCLC who were receiving
anti-PD-1 antibodies (e.g., nivolumab or pembrolizu-
mab) or anti-PD-L1 antibodies (e.g., atezolizumab or
durvalumab). The included patients could have received
previous oncologic therapy, but patients were excluded
if they had received anti-PD-1 antibodies or anti-PD-L1
antibodies in combination with other treatments such as
chemotherapy or other immunotherapies. XYS and SYC
screened the titles and abstracts of the search output to
assess whether the studies met the inclusion criteria, as
defined by the protocol. Then, they independently read
the full text of all potentially eligible studies for further
discrimination. Discrepancies between the two authors
regarding study inclusion were resolved via consensus
with the assistance of the senior authors (HJL and XL).
Outcomes
Incidence assessment was based on the number of global
and organ-specific irAEs (i.e., endocrine, gastrointestinal,
hepatic, pulmonary, renal, and skin diseases). IrAE sever-
ity was recorded as grade 1–5 based on version 3 or 4 of
the Common Terminology Criteria for Adverse Events
of the National Cancer Institute (Bethesda, MD, USA).
Grades 3 through 5 were considered high-grade irAEs.
Data extraction
Two authors (XYS and SYC) independently extracted
and recorded the data using Excel 2007. The data were
recorded on a predesigned extraction list. Full texts were
obtained through databases or by contacting the corre-
sponding authors. Discrepancies regarding data records
between the two authors were resolved via consensus
with the assistance of a senior author (XL).
Clinical trials were used to assess the incidence of
irAEs. Author(s), clinical trial information, study design,
enrollment size, type and dose of monoclonal antibodies,
version of the Common Terminology Criteria for Ad-
verse Events, frequency of irAEs and organ-specific
irAEs, and the median time to onset were captured for
the systematic review and meta-analysis.
Case reports were used to describe the diversity of
irAEs qualitatively. Patient characteristics, previous on-
cologic treatment, cancer outcome (i.e., oncologic re-
sponse or progressive disease), the nature of each irAE,
as well as irAE onset, treatment, and outcome were all
recorded.
Quality assessment
The Cochrane Collaboration “risk of bias” tool was used
to assess the risk of bias and to evaluate the quality of
RCTs that were included in the systematic review and
meta-analysis. Additionally, this tool was also used to
determine selection bias, performance bias, detection
bias, attrition bias, reporting bias, and other biases [13].
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The quality of non-RCTs was assessed by the Newcas-
tle–Ottawa Scale (NOS) [14]. Two authors (XYS and
TD) independently conducted this quality assessment,
and agreement was reached via consensus with the as-
sistance of a senior author (XL).
Data synthesis and analysis
The primary objective of this study was to determine the
incidence of irAEs for each treatment group (i.e.,
anti-PD-1 group and anti-PD-L1 group). The effect size
was a single proportion of incidence from each study be-
cause, some of the included studies were single-armed.
Statistical heterogeneity and inconsistency between the
selected studies were assessed using the Q statistic and
I2 statistic, respectively. The I2 cutoffs used to determine
inconsistency were very low (< 25%), low (25 to < 50%),
moderate (50 to < 75%), and large (> 75%). For each ana-
lysis, the 95% confidence interval (CI) of the weighted
average was calculated. If heterogeneity was not rejected
by the Q-test, the original random-effects model was
used because our analysis involved different populations
and the random-effects model incorporates interstudy
heterogeneity into the calculation [15, 16]. Before the
analyses, rate consolidation was conducted using five
methods (untransformed, log transformation, logit trans-
formation, arcsine transformation, and Freeman–Tukey
double arcsine transformation), and the method that
yielded results closest to a normal distribution was se-
lected. All analyses were conducted using the R package
Meta and function Metaprop (R version 3.4.4
[2018-3-15]; R Foundation, Vienna, Austria), which is
better able to achieve single-rate meta-analysis than the
method described in the published protocol for the R
package Meta. When the number of event counts was 0,
the classic value of 0.5 was used instead. The incidences
and their 95% CIs are presented as forest plots. Sub-
group analyses according to the type (anti-PD-1 or
anti-PD-L1) and brand of antibody drugs were per-
formed to avoid heterogeneity. Small-study effects were
assessed through a potentially more robust qualitative
(Doi plot) and quantitative (LFK index) approach with
MetaXL (MetaXL version 5.3; EpiGear International,
Noosa, Queensland, Australia) [17]. Influence analysis
was conducted by deleting each study from the model




Seven hundred ninety-nine articles were identified by
searching the literature databases, and six additional ar-
ticles were retrieved by manual searches. The titles and
abstracts were then read for these 805 articles, and 643
articles were excluded because they were duplicate
articles, included non-NSCLC tumors, or reported the
use of the inhibitors in combination with other drugs or
were review articles, basic research articles, or off topic.
One hundred sixty-two articles were ultimately fully
reviewed; of these, 43 studies were considered relevant
for the present study (16 clinical trials and 27 case re-
ports, Fig. 2). Per PRISMA guidelines, a reference list of
all excluded studies, except for those that were dupli-
cates, is provided with the reason(s) for exclusion before
each reference according to Fig. 2 (Additional file 2).
The meta-analysis thus included 16 clinical trials in
which patients were treated, based on the labeling of the
products (e.g., nivolumab at 1 mg/kg, 3 mg/kg, or 10 mg/
kg every 2 weeks; pembrolizumab at 2 mg/kg or 10mg/
kg every 3 weeks; durvalumab at 10 mg/kg every 2 weeks;
atezolizumab at 1200mg every 3 weeks; avelumab at 10
mg/kg every 3 weeks).
Incidence of irAEs: data from clinical trials
General characteristics
Sixteen clinical trials were included in the meta-analysis
for the current study. Only six articles recorded the total
and organ-specific irAEs. The remaining 10 articles de-
scribed only organ-specific irAEs. Because several irAEs
can occur in the same patient, the sum of the incidence
of organ-specific irAEs does not represent the overall
irAE incidence. Therefore, 2029 patients from six clinical
trials (three trials concentrated on anti-PD-1 treatment,
and three trials focused on anti-PD-L1 treatment) were
included in the meta-analysis to assess the global inci-
dence of irAEs [18–23]. In addition, 6208 patients from
16 clinical trials were included to assess the incidence of
organ-specific irAEs (Table 1) [18–33].
Most (15/16) studies were not blind. Nine of the stud-
ies were randomized, of which eight were controlled,
and seven of the studies were single-armed. Fourteen
studies were multicentered. The median follow-up dur-
ation for all clinical trials was 13months (interquartile
range [IQR], 10–15 months). It is noteworthy that pa-
tients with a history of autoimmune disease met the ex-
clusion criteria in all studies.
Global incidence of irAEs
The overall incidence of irAEs reported with anti-PD-1
and anti-PD-L1 treatment was 22% (95% CI, 17–28; I2,
90%) for all grades and 4% (95% CI, 2–6; I2, 60%) for
high grades (Fig. 3a and b). The incidence of all-grade
irAEs varied depending on drug type, from 27% (95% CI,
18–35; I2, 88%) for patients treated with PD-1 to 17%
(95% CI, 9–25; I2, 91%) for patients receiving PD-L1.
This drug effect was analogously confirmed in
high-grade irAEs, which showed incidences ranging
from 7% (95% CI, 2–12; I2, 65%) for PD-1 to 3% (95%
CI, 2–4; I2, 10%) for PD-L1 (Additional file 3: Figures S1
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and S2). No trials investigated the incidence of any grade
irAEs in patients treated with atezolizumab. Further,
only two clinical trials each assessed the incidence of
irAEs in patients treated with pembrolizumab [21, 22] or
durvalumab [18, 19]; one trial each assessed the inci-
dence of any grade irAEs in patients treated with nivolu-
mab [20] or avelumab [23], and one trial assessed the
incidence of high-grade irAEs in patients treated with
pembrolizumab [22]. Therefore, these studies were not
assessed in this meta-analysis (Additional file 3: Figures
S3 and S4).
Incidence of organ-specific irAEs
Organ-specific irAEs were observed with the highest in-
cidence in the endocrine system, skin, pulmonary tract,
and gastrointestinal tract, which were affected in 7%
(95% CI, 4–10), 5% (95% CI, 4–6), 4% (95% CI, 3–5),
and 4% (95% CI, 2–5) of cases, respectively. Hepatic or-
gans were affected in only 1% (95% CI, 1–2) of cases,
and other events, such as nephrologic, neurologic, car-
diologic, and hematologic diseases, were rare (< 1%).
Nearly all skin, endocrine, gastrointestinal, hepatic,
and renal irAEs were low-grade. High-grade irAEs repre-
sented 1% of pulmonary events (95% CI, 1–2; Fig. 3c
and Additional file 3: Figures S5 to S43).
Patients treated with PD-1 inhibitors tended to show a
higher incidence of organ-specific irAEs compared with
those treated with PD-L1 inhibitors, especially in the
gastrointestinal tract [9% (95% CI, 4–14%) vs. 1% (95%
CI, 0–1%)] and skin [10% (95% CI, 7–14%) vs. 1% (95%
CI, 0–2%)], although the rates of high-grade irAEs were
equivalent in the two groups (Fig. 3c; Additional file 3:
Figures S14 to S19 and Figures S40 to S46).
Incidence of death related to irAEs
Thirteen clinical trials reported the incidence of death
attributed to irAEs. In these studies, death occurred in
14 (0.34%) patients. Most deaths (79%) were related to
pneumonitis.
Nature of irAEs: data from case reports and retrospective
studies
General characteristics
Our research identified 35 patients from 27 case reports
with at least one irAE [34–60]. Three of these patients
presented with several irAEs. The general characteristics
of the patients are shown in Additional file 4: Table S2.
Thirty-two patients received anti-PD-1 treatment. Of
these, 74% received nivolumab treatment. Just one pa-
tient received anti-PD-L1 treatment. Seventeen (54%)
patients failed at least one course of chemotherapy be-
fore receiving anti-PD-1/anti-PD-L1 antibodies. The
irAEs manifested within a median of 10 (IQR, 6–19.5)
weeks. Ten patients continued to receive immunother-
apy after irAE diagnosis. The patients received a median
treatment of 6 (IQR, 2.25–11.25) cycles.
Fig. 2 Study flow chart for identification and selection of included studies
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Nature of irAEs
The most common organ-specific irAEs described in the
27 case reports of 35 patients occurred in the endocrine
system. Eleven (31%) cases were recorded and occurred,
on average, within 8.5 weeks of anti-PD-1/anti-PD-L1
treatment (Additional file 4: Table S2 and Table S3).
Adrenal crisis and diabetes were rare, and one case
study of diabetes reported that blood glucose levels were
elevated when the blood samples were tested before
treatment [36]. The irAEs reported in 6 of 11 clinical tri-
als resolved when treated by steroids and other symp-
tomatic drugs. Two cases of diabetes were also
controlled with insulin therapy. One report described
life-threatening adrenal crisis following nivolumab
treatment [45].
Pneumonitis was the most frequent pulmonary ad-
verse effect and is of particular relevance to NSCLC. It
was reported in up to 4% of all-grade irAEs and 1.5% of
high-grade irAEs in clinical trials [18–33]. Pneumonitis
tended to occur early, at a median time of 4.5 weeks
(IQR, 2.75–6.25) in four patients described in three case
reports, all of whom were treated with nivolumab (Add-
itional file 4: Table S3) [37, 40, 42]. The median duration
of immune treatment was 4.5 (IQR, 2.75–6.25) cycles,
implying that immunotherapy did not stop immediately
when pneumonitis occurred. Most of the initial symp-
toms were mild and presented as progressive dyspnea,
dry cough, and fever. These symptoms were readily con-
fused with lung cancer, which delayed the diagnosis. In
addition to clinical symptoms, the noted characteristics
included typical changes in ground glass opacity, reticu-
lar opacity, and consolidation distributed in the periph-
ery on CT.
Cutaneous irAEs are mostly described as rash and
pruritus. These are commonly reported in clinical trials,
second only to endocrine irAEs, and tend to be mild. Of
Table 1 Characteristics of studies included for the meta-analysis
Trial Design Design details Enrollment
size (no.)
Drug Dose (mg/kg) CTC for AE
version
Antonia (2017) [4] RCT double-blind, multicenter,
phase III
475 Durvalumab 10, q2w 4
Borghaei (2015) [5] RCT open-label, multicenter,
phase III
287 Nivolumab 3, q2w 4
Brahmer (2015) [6] RCT open-label, multicenter,
phase III
131 Nivolumab 3, q2w 4
Carbone (2017) [7] RCT open-label, multicenter,
phase III
267 Nivolumab 3, q2w 4
Fehrenbacher (2016) [8] RCT open-label, multicenter,
phase II
142 Atezolizumab 1200 mg, q3w 4
Garassino (2018) [9] Single-arm open-label, multicenter,
phase II
444 Durvalumab 10, q2w 4
Garon (2015) [10] Single-arm open-label, multicenter,
phase Ib
495 Pembrolizumab 2, q3w; 10, q3w; 10, q2w 4
Gettinger (2016) [11] Single-arm open-label, multicohort,
phase I
52 Nivolumab 3, q2w 4
Gettinger (2015) [12] RT dose-escalation cohort
expansion, phase I
129 Nivolumab 1,3,10,q2w 3
Herbst (2016) [13] RCT open-label, multicenter,
phase II/III
682 Pembrolizumab 2, 10, q3w 4
Peters (2017) [14] Single-arm open-label, multicenter,
phase II
659 Atezolizumab 1200 mg, q3w 4
Reck (2016) [15] RCT open-label, multicenter,
phase III
154 Pembrolizumab 200 mg q3w 4
Rittmeyer (2017) [16] RCT open-label, multicenter,
phase III
609 Atezolizumab 1200 mg q3w 4
Rizvi (2015) [17] Single-arm open-label, multicenter,
phase II
117 Nivolumab 3, q2w 4
Gulley (2017) [18] Single-arm open-label, multicenter,
phase II
184 Avelumab 10, q2w 4
Waterhouse (2018) [24] Single-arm open-label, community-
based, phase IIIb/IV
1420 Nivolumab 3, q2w 4
CTC for version, Common Terminology Criteria for Adverse Events version; RCT, Research clinical trial; n/a, not available
Sun et al. BMC Cancer          (2019) 19:558 Page 6 of 13
the three case reports of skin irAEs, two patients devel-
oped grade 3 skin adverse reactions: psoriasis occurred
at week 6 in one patient, while bullous pemphigoid oc-
curred at week 8 in the other patient (Additional file 4:
Table S3). Suspension of immunotherapy was the princi-
pal treatment. The combination of topical or intravenous
steroids with other therapies such as phototherapy also
promoted disease relief.
Nephrologic irAEs were rare. Most (80.0%; 4/5) cases
were diagnosed as acute interstitial nephritis by evidence
of kidney biopsy. Immune therapy was withdrawn, and
prednisone therapy was initiated from 60mg/day and ta-
pered over 1 month. The patients showed a prompt re-
turn to baseline kidney function [44].
Colitis was the most frequent gastrointestinal irAE in
clinical trials. However, possibly because of mostly mild
symptoms, we only retrieved one case report describing
pancreatitis [53], which presented after two cycles of
nivolumab with typical anorexia, vomiting, and back
pain. There were no abnormalities on CT or magnetic
resonance cholangiopancreatography. Prednisone was
administered up to 4mg/kg/day, and amylase and lipase
levels eventually returned to the normal range.
Other irAEs
Neurologic irAEs reported in the literature included one
case of cerebral vasculitis/encephalitis [39] and two cases
of myasthenia gravis [46, 51] (Additional file 4: Table
S3). The case of cerebral vasculitis/encephalitis resolved
through treatment with surgery and steroids. Although
immune therapy was discontinued, and steroids, plasma-
pheresis, and other adapted treatments were combined,
one patient with myasthenia gravis died, and one had
persistent myasthenia gravis symptoms.
Moreover, we retrieved two case reports describing peri-
cardial effusion [55, 60] and two case reports describing
myocarditis [50, 52], one of which was fatal. The patient
with myocarditis presented with acute right heart failure
and may have died of lethal cardiac arrhythmia 1 day after
hospitalization. At autopsy, a T cell-rich myocardial infil-
trate was identified, but an infectious cause was not identi-
fied [50]. In addition, authors in various studies reported
one case each of agranulocytosis [56], warm-autoimmune
hemolytic anemia [57], and immune thrombocytopenia
[58]. After administering methylprednisolone or dexa-
methasone and other symptomatic treatments, three cases
of hematologic irAEs were resolved.
Quality assessment
Most studies were open label, single-arm trials and
therefore had a high risk of selection bias, performance
bias, and detection bias. This problem is mostly un-
avoidable in clinical studies of oncology owing to ethical
considerations. Several researchers used a blinded, inde-
pendent, central review to assess tumor primary end-
points but not adverse events [18, 22, 26, 30]. All
included RCTs had low risks of reporting bias, attrition
bias, and other biases, and all non-RCTs had a high or
medium quality according to NOS for quality assess-
ment. Further details about the quality assessment are
available in Additional file 5: Table S4 and Table S5. The
LFK index values for quantitative assessment of the
small-study effects were more than 1 in the analysis of




Fig. 3 Incidence of global immune-related adverse events (irAEs) associated with anti-PD-1 and anti-PD-L1 antibodies: all grade (a) and severe
grade (b). Organ-specific irAEs associated with anti-PD-1 and anti-PD-L1 antibodies (c)
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(LFK: 1.17) irAEs with anti-PD-1 and anti-PD-L1, which
indicated that positive publication bias existed
(Additional file 6: Figure S45).
Discussion
The application of immunotherapy, especially PD-1/
PD-L1 inhibitors, has provided unprecedented efficacy
gains in NSCLC treatment. With the promotion of sin-
gle and joint application, two existing problems are be-
coming increasingly evident: unpredictable efficacy and
inevitable irAEs. To the best of our knowledge, our
study is the first meta-analysis and systematic review of
irAEs following treatment of NSCLC with anti-PD-1 or
anti-PD-L1. The most significant finding of the current
study was that the incidence of any grade irAEs with
anti-PD-1 treatment was higher than that with
anti-PD-L1 treatment, and the trend was consistent with
the incidence of high-grade irAEs. This finding was dif-
ferent from or even the opposite of the results of a pre-
vious systematic review that compared PD-1 inhibitors
with PD-L1 inhibitors (any grade, 16% vs. 11%; high
grade, 3% vs. 5%) [61]. This may be explained by the in-
creased number of included articles and the more expli-
cit definition of irAEs.
Organ-specific irAEs occurred most frequently in the
endocrine organs and skin, followed by the gastrointes-
tinal tract and the pulmonary tract. Liver-related and
kidney-related adverse reactions were rare. Adverse events
affecting the heart, blood, and nerves have also been re-
ported. The most frequent endocrine adverse effect was
thyroid dysfunction, which included six cases of
hypothyroidism, one case of hyperthyroidism, and one
case of thyroiditis. This irAE is usually detected 3–4 weeks
after drug intervention, with a trend of quick onset of
hyperthyroidism and short lag time to the development of
hypothyroidism [49]. The exact pathophysiology of
PD-1-associated thyroid dysfunction remains unclear.
However, unlike the slow progression of typical Hashimo-
to’s thyroiditis, the rapid course of PD-1-associated thy-
roid dysfunction suggests inflammatory destruction and
mechanisms similar to painless thyroiditis.
Symptoms such as fatigue, weight loss, cold intoler-
ance, and palpitations are common in oncology patients
and have a high possibility of being missed or misdiag-
nosed. Delays in diagnosis and management may lead to
worsening symptoms and further complications. There-
fore, specialists should be vigilant and rigorously moni-
tor confusing clinical symptoms and changes in
laboratory parameters to promptly identify and manage
irAEs. For example, thyroid changes are common after
treatment with PD-1 inhibitors and require active la-
boratory monitoring. TSH levels should thus be mea-
sured before initiating anti-PD-1/PD-L1 treatment and
every 4–6 weeks during treatment because nivolumab is
administered intravenously every 2 weeks and pembroli-
zumab is administered intravenously every 3 weeks [24].
In addition, we recommend that Common Terminology
Criteria self-reported by oncologists be used to supple-
ment physician evaluation [62].
Tissue pneumonia should be scrutinized to distinguish
between immune-related and non-immune-related dis-
ease. Asepticity of the bronchial and alveolar samples,
CD8+ lymphocyte-based alveolitis, and the presence of
lung immune-reactive processes are important refer-
ences for the diagnosis of immune-mediated organizing
pneumonitis [63]. Fortunately, most irAEs are highly
sensitive to corticosteroids, but recurrence due to pre-
mature tapering of steroids and possibly the long tissue
half-life of nivolumab is common [37]. One study on
colon irAEs reported that steroid sensitivity can be pre-
dicted by the colonic mucosal concentration of tumor
necrosis factor alpha [64]. Additionally, Stroud et al. [65]
used the interleukin 6 receptor antagonist tocilizumab to
effectively treat steroid-refractory irAEs. However, ran-
domized trials are required to more rigorously clarify
the relative efficacy and safety of these drugs.
It should be noted that case reports were included in
this review to qualitatively complement the quantitative
conclusions of the companion meta-analysis, and the
ability to draw statistical conclusions from case studies
is limited because only novel or rare irAEs tend to be re-
ported in the literature. Despite this limitation, the
current body of case studies does show that several ser-
ious irAEs have occurred in patients treated with
anti-PD-1/PD-L1 agents. However, immune-related
deaths are rare (0.34%), which is consistent with a review
of ICIs that reported that less than 1% of all patients had
fatal events associated with ICI [66]. Nonetheless, the in-
cidence of death due to irAEs in patients with NSCLC
was twice the incidence reported in a previous study of
malignancy (0.17%) [9].
The leading cause of death in the studies we reviewed
was pneumonitis, presumably because organ-specific
irAEs are related to tumor type. However, systematic re-
views of other tumor types will be required to verify this
finding.
An increasing number of lung cancer patients receive
first- or second-line immunotherapy; therefore, early
identification and management of irAEs is critical. Sev-
eral guidelines and reports on patient care have thus
been released. The European Society for Medical Oncol-
ogy Guidelines Committee has developed clinical prac-
tice guidelines for the use of five PD-1/PD-L1 inhibitors
alone, the use of ipilimumab alone, and the use of com-
bined ipilimumab and nivolumab [67]. Further, a con-
sensus statement from the Melanoma Nursing Initiative
on managing adverse events offers a positive, compre-
hensive nursing approach that gives clinicians resources
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to guide clinical care for patients who develop irAEs
while receiving anti-PD-1/PD-L1 therapy [68]. Addition-
ally, the Clinical Committee of the Endocrine Society
has approved the acute treatment guideline developed
by Higham et al. [69] for treating endocrine irAEs with
checkpoint inhibitors. Finally, one report each has
shared experiences in managing cutaneous irAEs [70]
and neurologic irAEs [71].
We did not examine differences in the incidence of
irAEs at different treatment doses because most reported
data only focus on trAEs, which do not exactly match
the definition of irAEs. However, the only RCT that has
evaluated the efficacy of pembrolizumab in patients with
previously treated PD-L1-positive NSCLC and advanced
NSCLC reported that adverse events of special interest
based on immune etiology occurred in 69 of 339 pa-
tients (20%) in the 2 mg/kg group and 64 of 343 patients
(19%) in the 10 mg/kg group [21]. A meta-analysis of
anti-PD-1/PD-L1 treatment for malignancy also reported
that the development of irAEs was unrelated to the dose
of PD-1/PD-L1 inhibitors [9]. Another clinical trial com-
pared the effect of different infusion times on the inci-
dence of irAEs in patients with previously-treated
advanced NSCLC and found that the overall frequency
of organ-specific irAEs was higher in the 30-min infu-
sion group than in the 60-min infusion group; however,
most events were mild, and the frequency of high-grade
irAEs was similarly low in both groups [33].
Our analysis showed that the incidence of irAEs is
higher with PD-1 inhibitors than with PD-L1 inhibitors.
PD-L1 inhibitors prevent PD-L1 from binding to PD-1,
but they do not prevent programmed cell death ligand 2
(PD-L2) from binding to PD-1, which may allow poten-
tial immune-related toxicity attributed to PD-L2 block-
ade to be avoided [72].
Another meta-analysis compared the efficacy of PD-1
and PD-L1 inhibitors in treating NSCLC and concluded
that the tumor response rate was higher in the
anti-PD-1 group than in the anti-PD-L1 group [10]. The
mechanism of tumor response is that PD-1 inhibitors
prevent the binding of protein PD-1 on the surface of
activated T cells to PD-L1 and PD-L2 on the surface of
tumor cells, thus restoring the function of T cells in the
immune system. PD-1 and PD-L1 are distributed not
only on T cells and tumor cells but also on various im-
mune cells such as B cells and macrophages. Thus, tox-
icity to normal organs is difficult to avoid. In addition,
recent research has shown that PD-L1-positive extracel-
lular vesicles participate in systemic resistance to
anti-tumor immunity when they are secreted by melan-
oma cells into the tumor microenvironment and circula-
tion [73]. This finding expanded a previously
unrecognized PD-1/PD-L1 interaction mechanism and,
to some extent, explained the correlation between high
risk rate and high response rate. This association is a re-
minder that specialists should seek a balance between gains
in efficacy and frequency/severity of adverse reactions.
Indeed, it should be noted that the role of PD-1/
PD-L1 inhibitors and agonists in predicting response
rates and improving efficacy also affects the incidence of
irAEs. For example, the main factors affecting the pem-
brolizumab response rate fall into two categories: those
associated with tumor neoepitope burden, such as high
tumor mutational burden, and those related to T
cell-inflamed tumor microenvironment, such as PD-L1
[74]. A combination of these predictive factors thus
helps to guide drug selection and to predict irAEs. It has
been shown that the number of genetic mutations in pa-
tients [75], the presence of CMTM6 molecules [76],
CD28/B7 status [77], and intestinal microbes [78] may
be associated with new antigens on the surface of cancer
cells, PD-L1 half-life, T cell activity, and T cell recruit-
ment, respectively. However, considering the high cost
of tumor mutational burden genome analysis and the
widespread application limits, novel markers that can be
directly detected by blood tests are needed, and the
threshold for these markers needs to be determined by
standardized experiments. Furthermore, it may be neces-
sary to discover new organ-specific indicators in order
to predict individual differences in organ-specific irAEs.
In summary, dynamic monitoring of the whole process
of drug penetration based on clear indicators and a more
thorough understanding of molecular mechanisms are
needed to establish an irAE-prediction system.
CTLA-4 inhibitors are a class of ICIs that were discov-
ered before PD-1/PD-L1 inhibitors. The overall incidence
of irAEs with these ICIs has been reported to be 72% for
all-grade malignant tumors and 24% for high-grade malig-
nant tumors [79]. This incidence was significantly higher
than that from treatment with PD-1/PD-L1 inhibitors,
reflecting the fact that these drugs have different mecha-
nisms of initiating anticancer immune attacks. Anti-PD-1
and anti-CTLA-4 treatments both induce the expansion
of specific subsets of tumor-infiltrating exhausted-like T
cells, and anti-CTLA-4 additionally engages ICOS+
Th1-like CD4 T cells [80]. The fact that these treatments
affect different T cell subsets explains why these therapies
are more effective when combined than when used alone.
Indeed, the histopathology of irAEs reflects these im-
munologic characteristics. For example, in PD-1
inhibitor-induced colitis, CD8+ T cells exist in the lamina
propria and epithelium, whereas the same T cells exist in
the lamina propria in CTLA-4 inhibitor-induced colitis
[64]. The FDA has approved the use of PD-1/PD-L1 in-
hibitors in combination with CTLA-4 antibodies for the
treatment of NSCLC, which represents an opportunity
and a challenge for specialists to more thoroughly under-
stand the irAEs induced by the two ICIs in combination.
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The irAEs reported after the deadline of the literature
search tended to be high-grade and fatal and include
hypophysitis [81], type I diabetes [82], and renal tubular
acidosis [83]. Renal tubular acidosis was reported for the
first time as an irAE associated with nivolumab. There is a
notable case report of a patient who experienced succes-
sive secondary adrenal insufficiency, thrombocytopenia,
and colitis, which were attributed to durvalumab [81]. In
addition, it was recently shown that influenza vaccination
in lung cancer patients can reduce the risk of complica-
tions but might increase the frequency of irAEs [84].
Our research had the following strengths. Firstly, our
study is the first meta-analysis and systematic evaluation
of irAEs after treatment of NSCLC with anti-PD-1 or
anti-PD-L1 and reconciled previous contradictory re-
sults. Secondly, the use of the Common Terminology
Criteria as an outcome metric for irAEs is clinically rele-
vant and readily interpretable by practicing oncologists.
Furthermore, the utilization of case reports in studies of
this nature is relatively novel, and a comprehensive re-
view of the treatment and prognosis status of irAEs
compensated for the weakness related to publication
bias to some extent. In addition, the integration of the
Cochrane risk of bias tool allowed us to highlight that
clinical studies of immunotherapy are often not random-
ized studies, but single-arm trials. Finally, the imputation
of event counts of zero with 0.5 allowed trials that did
not observe any adverse events to be included in the
meta-analysis and contribute valuable data. These ad-
vantages increased the relevance and improved the qual-
ity of our results, and strengthened the validity of the
conclusions.
On the other hand, several limitations should be
noted. First of all, only 16 studies that specifically re-
ported irAEs were included in this report, and the
remaining 10 studies only reported trAEs or did not fur-
ther clarify the incidence of any grade and high-grade
irAEs. This low proportion may be due to the need for a
clear definition of irAE and the corresponding difficulty
in diagnosing irAEs. Indeed, certain adverse events, such
as colitis, can occur because of a non-immune drug re-
sponse. Therefore, there is an urgent need to publish a
standardized method that specifies quantifiable criteria
for irAEs and non-irAEs. The irAEs described in this
study include those that were directly described in the
included clinical trials as well as select adverse events
and adverse events of special interest based on a prespe-
cified list of terms from the Medical Dictionary for
Regulatory Activities [85]. Secondly, this analysis was
based on articles that were published and indexed in one
of the databases or registries that were searched. It is
certainly plausible that publication of trials with unfavor-
able adverse event profiles, which may be more common
and more likely to have adverse consequences for
patients, was never pursued by the industry sponsor.
Thirdly, the included clinical studies described
single-arm trials, which are justified by the humanistic
approach to care required in oncology research. This
limitation does not allow the use of odds ratios to assess
the risk of adverse reactions. Moreover, three PD-L1 in-
hibitors were each approved for listing in the last 2 years;
therefore, there are fewer published clinical trials that
focus on these drugs. The incidence of irAEs for PD-L1
inhibitors thus needs to be further evaluated by future
updated studies. Finally, given that this study involved
an aggregate data meta-analysis, the potential for eco-
logical fallacy existed.
Conclusion
Wider applications of an increasing number of new
irAEs are being recognized. A thorough understanding
of the pathogenesis and pathologic features of these ad-
verse reactions can help to clarify the definition of irAEs
and to establish a predictive system to reduce morbidity.
At present, management guidelines for irAEs are grad-
ually being established. Timely and effective treatment
of irAEs is necessary to improve patient compliance and
guide decision-making for interruption of immunother-
apy. More in-depth clinical studies are required to iden-
tify biomarkers that are useful predictors of both
treatment efficacy and adverse effects and thereby allow
specialists to determine the optimal balance for effective
oncology treatment.
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